Program Oirector/Principal Investigator (Last, First, Middle): Bumett, John, C, Jr. PROJECT 3 Title: Maximizing the cGMP System in Preclinical Left Ventricular and Renal Dysfunction Project Description: Heart failure is a growing public health problem with high mortality and morbidity. The concept of preclinical heart failure is based on the fact that abnormal heart structure/function can be detected by complementary methods before the development of symptoms. Patients with those abnormalities may progress to symptomatic heart failure and are at increased risk of adverse cardiac events. This human translational project aims to develop novel therapeutics by maximizing the cGMP system using two FDA approved medications, Nesiritide and Tadalafil. to improve renal funcfion pafients with preclinical heart failure. Our goals are to further our understanding the cGMP pathway in the mechanism of renal dysfunction in preclinical heart failure and to develop therapies to improve the renal function with the hope of delaying the progression of preclinical heart failure to symptomatic heart failure. Project Leader: Horng H. Chen. MD;Associate Professor of Medicine Other

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Fayyaz, Ahmed U; Edwards, William D; Maleszewski, Joseph J et al. (2018) Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation 137:1796-1810
Kawakami, Rika; Lee, Candace Y W; Scott, Christopher et al. (2018) A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure. Clin Pharmacol Ther 104:546-552
Ichiki, Tomoko; Dzhoyashvili, Nina; Burnett Jr, John C (2018) Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. Int J Cardiol :
Cannone, Valentina; Buglioni, Alessia; Sangaralingham, S Jeson et al. (2018) Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population. Mayo Clin Proc 93:980-990
Saiki, Hirofumi; Petersen, Ivy A; Scott, Christopher G et al. (2017) Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. Circulation 135:1388-1396
Win, Sithu; Hussain, Imad; Hebl, Virginia B et al. (2017) Inpatient Mortality Risk Scores and Postdischarge Events in Hospitalized Heart Failure Patients: A Community-Based Study. Circ Heart Fail 10:
Sangaralingham, S Jeson; Wang, Bing H; Huang, Li et al. (2016) Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen. Peptides 76:108-14
McKie, Paul M; Schirger, John A; Benike, Sherry L et al. (2016) Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. Eur J Heart Fail 18:433-41
Holditch, Sara J; Schreiber, Claire A; Burnett, John C et al. (2016) Arterial Remodeling in B-Type Natriuretic Peptide Knock-Out Females. Sci Rep 6:25623
Lee, Candace Y W; Huntley, Brenda K; McCormick, Daniel J et al. (2016) Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. Eur Heart J Cardiovasc Pharmacother 2:98-105

Showing the most recent 10 out of 124 publications